Opinion
Video
T-DXd in Advanced Endometrial Cancer
Panelists discuss the recent tumor-agnostic approval of trastuzumab deruxtecan (T-DXd) based on findings from the DESTINY-PanTumor02 trial, exploring its implications for treatment approaches in advanced endometrial cancer, how to integrate T-DXd into treatment algorithms, patient selection criteria, and which patients are most likely to benefit from this therapy compared to lenvatinib/pembrolizumab.
Video content above is prompted by the following:
- Briefly comment on the recent tumor agnostic approval for trastuzumab deruxtecan (T-DXd) based on the findings from DESTINY-PanTumor02.
- How will this impact your treatment approach for patients with advanced endometrial cancer?
- Where will you integrate T-DXd into your treatment algorithm, how will you select patients for treatment, and which patients are most likely to benefit from this treatment approach?
- Talking points: T-DXd compared with use of lenvatinib/pembrolizumab
Related Videos
Related Content
